Search for a trial

A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

Primary objective: To evaluate the efficacy of JNJ-68284528 (Phase 2)Secondary objectives:# To characterize the safety of JNJ-68284528 (Phase 2)# To characterize the pharmacokinetics and pharmacodynamics of JNJ-68284528# To assess the immunogenicity…

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma

This study has been transitioned to CTIS with ID 2023-506587-13-00 check the CTIS register for the current data. The safety and efficacy of JNJ-68284528 in heavily pretreated patients with multiple myeloma is being evaluated in the Phase 1b/2 Study…

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

This study has been transitioned to CTIS with ID 2023-509848-10-00 check the CTIS register for the current data. Primary Objective: • Compare the efficacy of bb2121 to standard regimens in subjects with RRMM as measured by progression-free survival…

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma

This study has been transitioned to CTIS with ID 2023-506588-32-00 check the CTIS register for the current data. Primary objective: To compare the efficacy of JNJ-68284528 with standard therapy, either pomalidomide, bortezomib and dexamethasone (PVd…

A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma

This study has been transitioned to CTIS with ID 2023-503468-17-00 check the CTIS register for the current data. Primary- Part 1: To identify recommended Phase 2 doses and schedules (RP2Ds) for each combination.- Part 2: To characterize the safety…

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (study 208887 DREAMM 5)

DOSE EXPLORATION:Primary:To determine the safety and tolerability of GSK2857916 in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each sub-study combination treatment.Secondary:…

LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma

This study has been transitioned to CTIS with ID 2023-508101-24-00 check the CTIS register for the current data. The primary objective of the first randomized question (R1) open for allLBL patients (pts) of the core study cohort, is to evaluate…

Anakinra: safety and efficacy of interleukin-1 pathway inhibitor anakinra for the management of fever during neutropenia and mucositis in patients with multiple myeloma receiving an autologous hematopoietic stem cell transplantation after high-dose melphalan - A randomized controlled trial

The primary objective is to evaluate the efficacy of anakinra in patients with multiple myeloma receiving high-dose melphalan (HDM) in the preparation for an autologous hematopoietic stem cell transplantation (SCT). The primary endpoint is the…

Mast cells and fibrosis in myeloproliferative neoplasms.

The primary objective is to investigate the role of the hematopoeitic niche and mast cells in the bone marrow of MPN, and the effect of pharmacotherapy on these cells.

Whole blood thrombin generation, platelet activation test and platelet-monocyte complex formation to predict hypercoagulability in patients with multiple myeloma

To estimate the prothrombotic phenotype of patients with MM, on treatment with IMiD, using whole blood thrombin generation (WB-TG), platelet activation assays and PMC formation.

Molecular phenotyping of Mast Cells in Indolent Systemic Mastocytosis using Single Cell RNA-sequencing

To investigate which molecular mast cell phenotypes (as defined by the expressed genes and gene-networks) in bone marrow resident mast cells and their progenitors are associated with the presence or absence of ISM.

Immunological analyses of Long-term Molecular and Cellular Responses to Hymenoptera Venom Immunotherapy Indolent Systemic Mastocytosis patients.

The primary objective is to assess the adaptive T cell response to VIT in HVA patients with underlying ISM (ISM+) after treatment induction (at thirteen weeks) and upon reaching maintenance dose, after seven months, in comparison to the baseline…